Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Tatsuya TAMURA"'
Autor:
Hiroshi Noda, Makoto Okazaki, Eri Joyashiki, Tatsuya Tamura, Yoshiki Kawabe, Ashok Khatri, Harald Jueppner, John T Potts Jr, Thomas J Gardella, Masaru Shimizu
Publikováno v:
JBMR Plus, Vol 4, Iss 7, Pp n/a-n/a (2020)
ABSTRACT Prolonged signaling at the parathyroid hormone receptor 1 (PTHR1) correlates with the capacity of a ligand to bind to a G protein‐independent receptor conformation (R0). As long‐acting PTH (LA‐PTH) ligands hold interest as potential tr
Externí odkaz:
https://doaj.org/article/f46053afc9164d8fa153c2168e5cca83
Autor:
Tatsuya Tamura, Hiroshi Noda, Eri Joyashiki, Maiko Hoshino, Tomoyuki Watanabe, Masahiko Kinosaki, Yoshikazu Nishimura, Tohru Esaki, Kotaro Ogawa, Taiji Miyake, Shinichi Arai, Masaru Shimizu, Hidetomo Kitamura, Haruhiko Sato, Yoshiki Kawabe
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-14 (2016)
Hypoparathyroidism and osteoporosis can be treated with parathyroid hormone, but frequent injections are required. Here the authors develop a small-molecule agonist for the parathyroid hormone type I receptor that can be administered orally, and demo
Externí odkaz:
https://doaj.org/article/26ff462ed34f4f31ab3d012ea2e86ed2
Autor:
Yoshiaki Watanabe, Haruhiko Sato, Hidetomo Kitamura, Tomoya Kotake, Yoshikazu Nishimura, Masaru Shimizu, Takashi Emura, Kotaro Ogawa, Toru Esaki, Toshito Nakagawa, Akemi Mizutani, Yoshiyuki Furuta, Shinichi Arai, Hiroshi Noda, Masateru Ohta, Tatsuya Tamura, Yoshiaki Isshiki
Publikováno v:
Journal of Medicinal Chemistry. 63:5089-5099
We have previously shown that the oral administration of the small molecule hPTHR1 agonist PCO371 and its lead compound, 1 (CH5447240) results in PTH-like calcemic and hypophostemic activity in thyroparathyroidectomized rats. However, 1 was converted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e990e3b015767e8e07afcf1625e08030
https://doi.org/10.1021/acs.jmedchem.9b01743
https://doi.org/10.1021/acs.jmedchem.9b01743
Publikováno v:
Japanese Journal of Physical Education & Sport for Higher Education / Daigaku Taiiku Supotsugaku Kenkyu; Mar2023, Issue 20, p61-71, 11p
Autor:
Eri Joyashiki, John T. Potts, Masaru Shimizu, Hiroshi Noda, Makoto Okazaki, Yoshiki Kawabe, Tatsuya Tamura, Ashok Khatri, Harald Jueppner, Thomas J. Gardella
Publikováno v:
JBMR Plus
JBMR Plus, Vol 4, Iss 7, Pp n/a-n/a (2020)
JBMR Plus, Vol 4, Iss 7, Pp n/a-n/a (2020)
Prolonged signaling at the parathyroid hormone receptor 1 (PTHR1) correlates with the capacity of a ligand to bind to a G protein‐independent receptor conformation (R0). As long‐acting PTH (LA‐PTH) ligands hold interest as potential treatments
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23b49a9b9d8362120a42b3eab6add1ce
https://pubmed.ncbi.nlm.nih.gov/32666018
https://pubmed.ncbi.nlm.nih.gov/32666018
Autor:
Masaru Shimizu, Yoshikazu Nishimura, Masateru Ohta, Toshito Nakagawa, Yoshiyuki Furuta, Naoki Okamoto, Yoshiaki Isshiki, Haruhiko Sato, Yoshiaki Watanabe, Hitoshi Saito, Hiroshi Noda, Tatsuya Tamura, Tomoya Kotake, Toru Esaki
Publikováno v:
Journal of Medicinal Chemistry. 61:5949-5962
During the course of derivatization of HTS hit 4a, we have identified a novel small-molecule hPTHR1 agonist, 1-(3,5-dimethyl-4-(2-((2-((1R,4R)-4-methylcyclohexyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-1-methylurea (CH544724
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ee5e48d9dacf5c4280be8d1ffd84fb9
https://doi.org/10.1021/acs.jmedchem.8b00182
https://doi.org/10.1021/acs.jmedchem.8b00182
Autor:
Tohru Esaki, Eri Joyashiki, Kotaro Ogawa, Tomoyuki Watanabe, Taiji Miyake, Hidetomo Kitamura, Tatsuya Tamura, Shinichi Arai, Masaru Shimizu, Hoshino Maiko, Masahiko Kinosaki, Yoshikazu Nishimura, Yoshiki Kawabe, Haruhiko Sato, Hiroshi Noda
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-14 (2016)
Nature Communications
Nature Communications
Parathyroid hormone (PTH) is essential for calcium homeostasis and its action is mediated by the PTH type 1 receptor (PTHR1), a class B G-protein-coupled receptor. Hypoparathyroidism and osteoporosis can be treated with PTH injections; however, no or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96bf93859661c7e6d366e09a8ba8bea6
https://doaj.org/article/26ff462ed34f4f31ab3d012ea2e86ed2
https://doaj.org/article/26ff462ed34f4f31ab3d012ea2e86ed2
Autor:
Makoto Okazaki, John T. Potts, Kenji Adachi, Hiroshi Noda, Miho Nagayasu, Thomas J. Gardella, Masaru Shimizu, Tomoyuki Watanabe, Tatsuya Tamura, Eri Joyashiki, Yoshiki Kawabe
Publikováno v:
Journal of Bone and Mineral Research. 31:1405-1412
Hypoparathyroidism is a disease of chronic hypocalcemia and hyperphosphatemia due to a deficiency of parathyroid hormone (PTH). PTH and analogs of the hormone are of interest as potential therapies. Accordingly, we examined the pharmacological proper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e149aebc7e5903ef93f866ddc0cce3a
https://doi.org/10.1002/jbmr.2811
https://doi.org/10.1002/jbmr.2811
Autor:
Eri Joyashiki, Masaru Shimizu, Chisato Miyaura, Hiroshi Noda, Tatsuya Tamura, Akira Hayasaka, Masahiko Nanami, Chie Nakagawa, Motohiro Kato, Kentaro Asanuma, Masaki Inada
Publikováno v:
Biological & Pharmaceutical Bulletin. 39:625-630
Parathyroid hormone (PTH) is a potential medicine for osteoporosis, and subcutaneous (s.c.) PTH treatment enhances bone mass; however, continuous infusion of PTH elicits bone resorption and induces bone loss. To clarify this contradictory phenomenon,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af782238ab8a52739c2a5984c71a8a2f
https://doi.org/10.1248/bpb.b15-00756
https://doi.org/10.1248/bpb.b15-00756
Publikováno v:
Japanese Journal of Physical Education & Sport for Higher Education / Daigaku Taiiku Supotsugaku Kenkyu; Mar2021, Issue 18, p162-169, 8p